Although we did not establish the specific glycosylation sites that affect the fibrogenic effect of GPNMB, the experimental results suggest that altered glycosylation levels of GPNMB affect its EMT function to some extent, suggesting that GPNMB represents a novel therapeutic target for pulmonary fibrosis. This evidence concerns the gene GPNMB and pulmonary fibrosis.